title: Antibiotic prophylaxis and prosthetic valve endocarditis.
abstract: Early onset prosthetic valve endocarditis is one of the most lethal complications after valve replacement. During the first year of operation of our new cardiac surgical program, we observed 10 cases of prosthetic valve endocarditis, the majority being caused by staphylococci, making an incidence of 10.6%. Subsequent investigations uncovered a very high prevalence of methicillin-resistant strains which led to a radical change in the antibiotic prophylaxis, from a cephalosporin-based protocol to a two drug regime of vancomycin and netilmicin. There were no cases of prosthetic infection among the 138 patients operated on in the one year period following the institution of this protocol. Because there were no other changes, either in the types of prostheses used or the techniques of implantation, the eradication of prosthetic valve endocarditis can be related only to this alteration in the prophylaxis. Therefore, we may conclude that the inter-institutional transfer of protocols is not adequate before a thorough investigation of the prevalent hospital pathogens and their sensitivity to antibiotics is carried out. We have not registered resistances to vancomycin and this drug remains the most important antimicrobial agent, both in the prophylaxis and in the treatment of prosthetic valve endocarditis.
authors.affiliation: Division of Cardiothoracic Surgery, University Hospital, Coimbra, Portugal.
authors.forename: M J
authors.initials: MJ
authors.lastname: Antunes
authors.forename: M F
authors.initials: MF
authors.lastname: Sanches
authors.forename: L E
authors.initials: LE
authors.lastname: Fernandes
mesh_terms: D000328:Adult; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D004697:Endocarditis, Bacterial / Q000382:microbiology / Q000517:prevention & control*; D005260:Female; D006350:Heart Valve Prosthesis / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009428:Netilmicin / Q000627:therapeutic use; D016459:Prosthesis-Related Infections / Q000382:microbiology / Q000517:prevention & control*; D013203:Staphylococcal Infections / Q000382:microbiology / Q000517:prevention & control; D013212:Staphylococcus epidermidis / Q000187:drug effects / Q000302:isolation & purification; D014640:Vancomycin / Q000627:therapeutic use
chemical_list: D009428:Netilmicin; D014640:Vancomycin